{
    "clinical_study": {
        "@rank": "87454", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Atomoxetine", 
                "arm_group_type": "Experimental", 
                "description": "atomoxetine (40 mg/day)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate atomoxetine's effects on the rewarding and\n      reinforcing effects of nicotine in a controlled human laboratory study with 24 otherwise\n      healthy nicotine dependent subjects. It is hypothesized that atomoxetine will attenuate the\n      negative effects of nicotine."
        }, 
        "brief_title": "Atomoxetine's Effects On Nicotine Response And Stress Response In Smokers", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Nicotine Dependence", 
        "condition_browse": {
            "mesh_term": "Tobacco Use Disorder"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  female and male smokers, not treatment seeking,  aged 18 to 55 years;\n\n          -  history of smoking daily for the past 12 months, at least 5 cigarettes daily;\n\n          -  CO level > 10ppm;\n\n          -  for women: not pregnant as determined by pregnancy screening, nor breast feeding, and\n             using acceptable birth control methods.\n\n        Exclusion Criteria:\n\n          -  history of major medical illnesses including asthma or chronic obstructive lung\n             disease, history or current gastrointestinal ulcer, hepatic or renal impairment,\n             coronary artery disease, cardiac rhythm disturbances or other medical conditions that\n             the study physician deems contraindicated for the subject to be in the study;\n\n          -  regular use of psychotropic medication (antidepressants, antipsychotics, or\n             anxiolytics)\n\n          -  recent psychiatric diagnosis and treatment for Axis I disorders including major\n             depression, bipolar affective disorder, schizophrenia and panic disorder within the\n             past year. We will make an exception for the following Axis I diagnoses: nicotine\n             dependence and alcohol or other drug dependence (i.e., cocaine, opioid) as long as\n             they are not meeting abuse or dependence criteria within the past 3 months for\n             alcohol or drug use;\n\n          -  use of  drugs that slow heart rate (eg, beta-blockers), which may increase the risk\n             of bradycardia and AV block, or NSAIDs, which may increase potential for developing\n             ulcers/active or occult gastrointestinal bleeding;\n\n          -  known allergy to atomoxetine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02046551", 
            "org_study_id": "AArias11.12.13"
        }, 
        "intervention": {
            "arm_group_label": "Atomoxetine", 
            "intervention_name": "Atomoxetine", 
            "intervention_type": "Drug", 
            "other_name": "Strattera"
        }, 
        "intervention_browse": {
            "mesh_term": "Atomoxetine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "nicotine", 
            "smoking", 
            "atomoxetine", 
            "stress"
        ], 
        "lastchanged_date": "May 1, 2014", 
        "location": {
            "contact": {
                "email": "albert.arias@yale.edu", 
                "last_name": "Albert Arias, MD", 
                "phone": "203-932-5711", 
                "phone_ext": "4471"
            }, 
            "facility": {
                "address": {
                    "city": "West Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06515"
                }, 
                "name": "West Haven Veterans Affairs"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "albert.arias@yale.edu", 
            "last_name": "Albert Arias, MD", 
            "phone": "203-932-5711", 
            "phone_ext": "8155"
        }, 
        "overall_official": {
            "affiliation": "Yale University", 
            "last_name": "Albert Arias, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Subjects will rate 6 items that are related to nicotine effect on a 100 mm scale, \"not at all\" to \"extremely.\" The items are feeling the drug strength, feel \"good\" drug effects, feel \"bad\" drug effects, feel jittery, feel stimulated, and head rush. This instrument is an abbreviated version of a visual analog scale (VAS) and allows rapid detection of nicotine effects.", 
                "measure": "Nicotine Effects Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }, 
            {
                "description": "Subjects will rate 6 items that are related to nicotine effect on a 100 mm scale, \"not at all\" to \"extremely.\" The items are feeling the drug strength, feel \"good\" drug effects, feel \"bad\" drug effects, feel jittery, feel stimulated, and head rush. This instrument is an abbreviated version of a visual analog scale (VAS) and allows rapid detection of nicotine effects.", 
                "measure": "Nicotine Effects Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Day 17"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02046551"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The Center for Epidemiologic Studies Depression (CES-D) scale is a 20-item self-report measure of depressive symptoms. The range of scores is from 0 to 60, with higher scores reflecting increased depressive symptoms 41. The CES-D does not heavily depend on pathological items compared with other scales such as the Beck Depression Inventory and does not define clinical depression.", 
                "measure": "Center for Epidemiologic Studies Depression (CES-D) scale", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }, 
            {
                "description": "Positive and Negative Affect Schedule (PANAS ) is a 20-item scale that assesses both negative and positive affective states. Subjects rate adjectives describing affective states on a scale of 1 to 5 using a specified time period (e.g., now, today, past week etc.). Scores are then added up to generate negative and positive scale scores.", 
                "measure": "Positive and Negative Affect Schedule (PANAS )", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }, 
            {
                "description": "The Profile of Mood States (POMS) is a 72-item questionnaire which consists of adjectives commonly used to describe momentary mood states. It has been found to be sensitive to the mood-altering effects of drugs including nicotine. POMS has a 5-point objective rating scale (0=not at all to 5=extremely). There are eight mood states that this scale measures: (1) Anger, (2) Anxiety, (3) Confusion, (4) Depression, (5) Elation, (6) Fatigue, (7) Friendliness and (8) Vigor. POMS will be used during each session to measure effects of atomoxetine or nicotine on mood.", 
                "measure": "The Profile of Mood States (POMS)", 
                "safety_issue": "No", 
                "time_frame": "Day  5"
            }, 
            {
                "description": "The Center for Epidemiologic Studies Depression (CES-D) scale is a 20-item self-report measure of depressive symptoms. The range of scores is from 0 to 60, with higher scores reflecting increased depressive symptoms 41. The CES-D does not heavily depend on pathological items compared with other scales such as the Beck Depression Inventory and does not define clinical depression.", 
                "measure": "Center for Epidemiologic Studies Depression (CES-D) scale", 
                "safety_issue": "No", 
                "time_frame": "Day 17"
            }, 
            {
                "description": "Positive and Negative Affect Schedule (PANAS ) is a 20-item scale that assesses both negative and positive affective states 44. Subjects rate adjectives describing affective states on a scale of 1 to 5 using a specified time period (e.g., now, today, past week etc.). Scores are then added up to generate negative and positive scale scores.", 
                "measure": "Positive and Negative Affect Schedule (PANAS )", 
                "safety_issue": "No", 
                "time_frame": "Day 17"
            }, 
            {
                "description": "The Profile of Mood States (POMS) is a 72-item questionnaire which consists of adjectives commonly used to describe momentary mood states. It has been found to be sensitive to the mood-altering effects of drugs including nicotine. POMS has a 5-point objective rating scale (0=not at all to 5=extremely). There are eight mood states that this scale measures: (1) Anger, (2) Anxiety, (3) Confusion, (4) Depression, (5) Elation, (6) Fatigue, (7) Friendliness and (8) Vigor. POMS will be used during each session to measure effects of atomoxetine or nicotine on mood.", 
                "measure": "The Profile of Mood States (POMS)", 
                "safety_issue": "No", 
                "time_frame": "Day 17"
            }, 
            {
                "description": "In order to monitor adverse events from the study medications, SCF will be administered before and after each session. SCF is a locally developed symptom checklist that includes possible side effects of study medications with each symptom being scored 1-5.", 
                "measure": "Symptom Checklist Form (SCF)", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }, 
            {
                "description": "In order to monitor adverse events from the study medications, SCF will be administered before and after each session. SCF is a locally developed symptom checklist that includes possible side effects of study medications with each symptom being scored 1-5.", 
                "measure": "Symptom Checklist Form (SCF)", 
                "safety_issue": "No", 
                "time_frame": "Day 17"
            }, 
            {
                "description": "Smokers will be asked to rate several nicotine withdrawal symptoms on a likert scale visual analogue. There are 12 items responses range from 0, \"not at all\" to 3 \"extremely\".", 
                "measure": "Nicotine Withdrawal Symptom Checklist (NWSC)", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }, 
            {
                "description": "Smokers will be asked to rate several nicotine withdrawal symptoms on a likert scale visual analogue. There are 12 items responses range from 0, \"not at all\" to 3 \"extremely\".", 
                "measure": "Nicotine Withdrawal Symptom Checklist (NWSC)", 
                "safety_issue": "No", 
                "time_frame": "Day 17"
            }
        ], 
        "source": "Yale University", 
        "sponsors": {
            "collaborator": {
                "agency": "Department of Veterans Affairs", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}